ADVAIR DISKUS 100/50 Drug Patent Profile

When do Advair Diskus 100/50 patents expire, and what generic alternatives are available?

Advair Diskus 100/50 is a drug marketed by Glaxo Grp Ltd and is included in one NDA.

The generic ingredient in ADVAIR DISKUS 100/50 is fluticasone propionate; salmeterol xinafoate. There are twenty-nine drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the fluticasone propionate; salmeterol xinafoate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Advair Diskus 100/50

A generic version of ADVAIR DISKUS 100/50 was approved as fluticasone propionate; salmeterol xinafoate by HIKMA on December 17^th, 2020.

Summary for ADVAIR DISKUS 100/50

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ADVAIR DISKUS 100/50

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxo Grp Ltd	ADVAIR DISKUS 100/50	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	021077-001	Aug 24, 2000	AB	RX	Yes	Yes

International Patents for ADVAIR DISKUS 100/50

See the table below for patents covering ADVAIR DISKUS 100/50 around the world.

Country	Patent Number	Title	Estimated Expiration
Zimbabwe	6584	PHENETHANOLAMINE DERIVATIVES
Hungary	213221	INHALATION DEVICE AND MEDICINE PACKET FOR DEVICE
Japan	H03858
Italy	8147792
Australia	5926794
Kenya	3864	PHENETHANOLAMINE DERIVATIVES

Supplementary Protection Certificates for ADVAIR DISKUS 100/50

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1519731	13C0067	France		PRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215
1519731	92269	Luxembourg		PRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
2506844	132018000000341	Italy		PRODUCT NAME: UN PRODOTTO DI COMBINAZIONE FARMACEUTICA COMPRENDENTE UN SALE FARMACEUTICAMENTE ACCETTABILE DI UMECLIDINIO (AD ESEMPIO BROMURO DI UMECLIDINIO), VILANTEROLO O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE (AD ESEMPIO VILANTEROLO TRIFENATATO) E UN FUROATO(TRELEGY ELLIPTA - FLUTICASONE FUROATO/UMECLIDINIO/VILANTEROLO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1236, 20171117
2506844	18C1022	France		PRODUCT NAME: COMBINAISON COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (EN PARTICULIER LE BROMURE D'UMECLIDINIUM), DU VILANTEROL OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI (EN PARTICULIER LE TRIFENATATE DE VILANTEROL), ET DU FUROATE DE FLUTICASONE; REGISTRATION NO/DATE: EU/1/17/1236 20171117
1519731	132013902182575	Italy		PRODUCT NAME: AZELASTINA CLORIDRATO/FLUTICASONE PROPIONATO(DYMISTA); AUTHORISATION NUMBER(S) AND DATE(S): 2011/07125-REG, 20111024;041808015/M-027/M-039/M-041/M, 20130527
0416951	12/1999	Austria		PRODUCT NAME: SALMETEROL, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, EINSCHLIESSLICH DES 1-HYDROXY-2-NAPHTHOATS (XINAFOAT) UND FLUTICASON PROPIONAT; NAT. REGISTRATION NO/DATE: 1-22897,1-22898, 1-22899,1-22900, 1-22901,1-22902 19990204; FIRST REGISTRATION: SE 14591-14596 19980907

ADVAIR DISKUS 100/50 (fluticasone propionate 100 mcg / salmeterol 50 mcg): Investment scenario and fundamentals analysis

Last updated: April 25, 2026

What is ADVAIR DISKUS 100/50 and what product economics matter?

ADVAIR DISKUS 100/50 is a dry powder inhaler (DPI) formulation combining:

• Fluticasone propionate (inhaled corticosteroid, ICS) 100 mcg
• Salmeterol xinafoate (long-acting beta2-agonist, LABA) 50 mcg
  Delivered as one inhalation per blister; the label uses a twice-daily dosing schedule for most patients. The product class is a chronic maintenance therapy for:
• Asthma (in appropriate patients)
• COPD (in appropriate patients under labeled use)

ADVAIR DISKUS is marketed in the US by GlaxoSmithKline (GSK). The key fundamental variables for investment analysis are the durability of ICS/LABA franchise economics (breath-actuated adherence, payer coverage), the erosion risk from generics and competitor inhaler ecosystems, and litigation and patent-life dynamics for the specific strengths and device platform.

Which fundamentals define demand durability?

1) Indication base and chronic use

ADVAIR DISKUS is a maintenance DPI intended for long-term control, not acute rescue. That structural demand profile typically supports stable base volumes when:

• guideline positioning stays intact
• payers continue to cover the category
• patients remain on the inhaler rather than switch to newer devices/classes

2) Competitive pressure inside ICS/LABA

The ICS/LABA space faces competition from:

• other brands in DPI and HFA inhalers
• combination therapies with different device and dosing convenience
• payer-driven substitution toward lower-cost alternatives

For ADVAIR DISKUS 100/50, competitive intensity is less about efficacy discrimination within the class and more about formulary placement (preferred tier status), copay structure, and device switching frictions.

3) Device and adherence economics

ADVAIR DISKUS is a DPI that relies on patient inhalation technique. Switching to other devices (different resistance, plume characteristics) changes adoption and can affect persistence. Persistence is a major determinant of lifetime value for chronic respiratory franchises.

What does the label imply about regimen and utilization?

The FDA-approved labeling for ADVAIR DISKUS positions the product as twice-daily maintenance therapy and includes safety communications tied to LABA class risks and inhaled corticosteroid adverse effects (notably pneumonia risk in COPD populations and class warnings). The label also contains instructions for use, dose titration logic, and constraints around LABA duplication.

Core utilization implication: because patients are expected to take it on schedule, the product tends to show better sales resilience than episodic respiratory therapies when coverage remains stable.

(See FDA labeling for dosing and safety framework.) [1]

How exposed is ADVAIR DISKUS to patent and exclusivity outcomes?

1) Market reality: legacy ICS/LABA blockbuster with long-run pricing pressure risk

ADVAIR DISKUS is a long-established product. For investment, the critical point is not whether it had patents historically, but whether near-term legal or exclusivity events could materially change supply, pricing, and payer coverage.

For the platform economics of a legacy inhaler, the dominant risk drivers are typically:

• generic and authorized-duplicate penetration
• manufacturing and supply stability
• litigation outcomes that affect exclusivity windows
• payer contracting shifts that move the product from preferred to non-preferred tiers

2) What matters specifically for the 100/50 strength

Strength-specific exposure matters because formularies sometimes treat strengths differently (e.g., 100/50 vs 250/50) based on dosing needs, clinical selection, and step-up/step-down patterns. A strength that maps to smaller patient segments can show different elasticity under substitution versus the most commonly used strength.

However, in the absence of strength-level exclusivity triggers in the provided record, the investment implication is to treat 100/50 as a subset within the ADVAIR franchise, whose trend is driven by the broader competitive and reimbursement environment for the brand.

What is the investment scenario for ADVAIR DISKUS 100/50: base case, bear case, bull case?

Base case: stable-to-declining but resilient chronic revenue

Assumptions consistent with legacy ICS/LABA market structure:

• ADVAIR DISKUS continues to have some formulary coverage and brand preference in a subset of plans.
• Patient persistence remains moderate due to chronic use and inertia.
• Price realization declines slowly versus earlier years due to generic penetration and contracting.

Fundamental read-through:

• Revenue declines are typically driven by gradual mix shift, tier changes, and substitution, not sudden demand destruction.
• The twice-daily regimen helps adherence, but device-class substitution can still occur.

Bear case: faster tier erosion and substitution

Key triggers:

• further formulary de-listing to tier-2 or tier-3 status
• aggressive pharmacy benefit manager (PBM) contracting with lower-cost alternatives
• increased switching to other inhaler platforms due to convenience and clinician-patient preference shifts

What this would do to fundamentals:

• lower prescription volume
• worse net price due to higher rebates and utilization management
• higher promotional intensity to defend share

Bull case: payer retention and mix stabilization

Key triggers:

• sustained preferred placement in respiratory formularies
• stable prescriber preference for DPI workflows in asthma/COPD step therapy
• limited generic or competitive displacement within the 100/50 dosing niche

Fundamental outcome:

• smaller-than-expected erosion in scripts
• more stable prescription mix across strengths

What are the key downside and upside signals to monitor?

Downside signals

• PBM contract changes that reduce net price or shift to non-preferred tiers
• evidence of accelerated patient switching to other ICS/LABA device formats
• any safety-driven changes in prescribing behavior tied to label warnings (class-level dynamics)

Upside signals

• stable formulary positioning in high-volume plan segments
• growth in patient persistence or reduced discontinuation rates in real-world claims datasets
• stable prescription mix within ADVAIR DISKUS strengths due to clinician step-down/up patterns

How do label-driven safety communications affect risk-adjusted forecasts?

The ADVAIR DISKUS label includes LABA class warnings and safety content relevant to chronic respiratory populations. Investment implication: in respiratory categories, safety communications influence:

• prescriber comfort
• patient willingness to initiate or continue therapy
• payer utilization management intensity

From an earnings-quality standpoint, label risk is typically a slower-moving headwind versus an immediate demand shock unless it leads to abrupt guideline or payer policy changes. The label’s structure points to ongoing risk management in chronic populations. [1]

Key competitive and portfolio context for GSK respiratory inhalers

ADVAIR DISKUS sits inside GSK’s broader respiratory franchise, which spans multiple inhaler platforms. Competitive dynamics are shaped by:

• brand portfolios across asthma and COPD
• device families and patient familiarity
• contracting and substitution policies across PBMs

Investment logic is that ADVAIR DISKUS can underperform if it loses formulary position, but can stabilize if it remains embedded in chronic treatment pathways and retains a loyal prescribing base.

What does the “100/50” strength imply for patient segment economics?

The 100/50 strength is typically used for asthma or COPD maintenance in patients whose disease control and exacerbation risk profile aligns with that dosing step. That places the product in a segment defined by:

• step therapy selection
• clinician titration behavior (up-step if uncontrolled, down-step if controlled)
• patient tolerability and control goals

Investment impact: 100/50 tends to be more sensitive to step-therapy dynamics than higher-strength “step-up” dosing in some populations, so scripts can shift with guideline interpretation and outcomes-based payer management.

Investment checklist: what to validate in diligence for ADVAIR DISKUS 100/50

1. Formulary status by payer tier for asthma and COPD coverage rules
2. Net price and rebate trajectory for the ADVAIR DISKUS franchise, then isolate 100/50 mix
3. Prescription persistence (time on therapy) and switching rates to alternative ICS/LABA devices
4. Claims-based trend in asthma vs COPD share within 100/50 usage
5. Competition mapping by device and molecule pair, focusing on those with preferred PBM access
6. Regulatory and labeling stability (no sudden revisions changing standard of care)

Key Takeaways

• ADVAIR DISKUS 100/50 is a chronic maintenance ICS/LABA DPI with demand durability tied to persistence, formulary positioning, and device switching behavior.
• The primary investment risk is not clinical efficacy but pricing and utilization pressure from legacy molecule competition and payer contracting.
• The investment opportunity (if any) depends on whether the product maintains preferred tier status and stable 100/50 mix amid broader ICS/LABA displacement.
• Safety communications in the label matter mainly through prescriber and payer behavior over time rather than immediate volume collapse. [1]

FAQs

1) What drug components are in ADVAIR DISKUS 100/50?
Fluticasone propionate 100 mcg and salmeterol xinafoate 50 mcg per inhalation. [1]

2) Is ADVAIR DISKUS 100/50 a rescue medicine?
No. It is indicated for maintenance therapy; it is not a rescue inhaler. [1]

3) What is the dosing schedule implied by the label?
The product is intended as a twice-daily maintenance regimen for patients. [1]

4) What category risks affect the long-run forecast for ADVAIR DISKUS?
LABA class warnings and inhaled corticosteroid-related risks can shape prescribing and payer utilization management. [1]

5) What drives the biggest upside or downside in a legacy ICS/LABA inhaler investment thesis?
Formulary tier status, net price/rebate trajectory, and patient persistence versus switching to competing ICS/LABA inhalers and devices.

---

References

[1] FDA. (n.d.). ADVAIR DISKUS (fluticasone propionate and salmeterol inhalation powder), prescribing information. US Food and Drug Administration. https://www.accessdata.fda.gov/